Document:

Base Salaries of Executive Officers of the Company

 Exhibit 10.26 
 BASE SALARIES OF EXECUTIVE OFFICERS OF THE REGISTRANT 
 As of March 15, 2006, the following are
the base salaries (on an annual basis) of the executive officers of Iomega Corporation: 
  

				
	 Jonathan S. Huberman
	  	$	500,000
	 Vice Chairman and Chief Executive Officer
	  		
	 Anna L. Aguirre
	  	$	190,000
	 Vice President, Human Resources and Facilities
	  		
	 Ronald J. Gillies
	  	$	275,000
	 Vice President and General Manager, Americas
	  		
	 Thomas D. Kampfer
	  	$	300,000
	 President, Chief Operating Officer and Interim Chief Financial Officer
	  		
	 Ulrike Tegtmeier (base salary in Swiss Francs CHF 380,000)
	  	$	288,861
	 Vice President, Managing Director, International SalesIomega 2006 Incentive Bonus Plan

 Exhibit 10.27 
 Iomega 2006 Profit Sharing and IBP Programs 
 Background for Plans 
  

	 	•	 	For Fiscal Year 2006, the Board of Directors has recognized the need to provide an incentive to employees to facilitate the goal to return the company to sustained profitability and
instill a culture individual accountability. 

  

	 	•	 	The Board of Directors further recognized: 

  

	 	•	 	Contractual agreements with many employees to provide bonus metrics each fiscal year, and 

  

	 	•	 	Potential employee retention & morale improvements related to a bonus incentive opportunity based on individual contributions to corporate objectives as well as unified
corporate goals 

 2006 IBP Program 
 Plan Structure: 
  

	 	•	 	75% of bonus based on annual corporate metrics (paid annually) 

  

	 	•	 	Executive plan participants are weighted 100% on corporate metrics. Budget compliance by a participant is a threshold requirement for any payout. 

  

	 	•	 	Corporate participants are weighted 50% on corporate-wide metrics based on operating earnings; Regional participants are weighted 25% on corporate-wide metrics and 25% on regional
specific metrics both based on operating earnings 

  

	 	•	 	Calculation formula 

  

	 	•	 	First payout level is 80% of target bonus for 80% metric achievement 

  

	 	•	 	100% payout level is reached at 100% metric achievement 

  

	 	•	 	The maximum payout is 200% of target bonus payout if established metrics are reached 

  

	 	•	 	25% of bonus based on Key Performance Indicator’s (KPIs) set and measured for the 2nd Half of 2006. 

  

	 	•	 	KPIs are scored and weighted with a range of payout from zero to a maximum 150% 

  

	 	•	 	KPI portion of the IBP can payout as long as the corporation is profitable (including cost of KPI payout) in the KPI period 

 2006 Profit Sharing Program 
 Plan Structure: 
  

	 	•	 	Q1 and Q2 plan based on stand alone quarterly corporate metrics (no region metrics/targets) 

  

	 	•	 	Q3 and Q4 regional metrics will be included. Regional participants plan is based 50% on corporate targets and 50% on regional targets 

	 	•	 	Calculation formula 

  

	 	•	 	First payout level is 80% of target bonus for 80% metric achievement 

  

	 	•	 	100% payout level is reached at 100% metric achievement 

  

	 	•	 	The maximum payout is 200% of target bonus payout if established metrics are reached 

 Administrative Details 
  

	 	•	 	Payout calculations will occur upon the official close of the: 

  

	 	•	 	Quarter for the Profit Sharing Program with any payments occurring by the first payroll of the 2nd month of the following quarter 

  

	 	•	 	Fiscal year for the annual corporate objectives with any payments generally occurring in early February 

  

	 	•	 	Operating income calculations will exclude extraordinary events, as determined by the sole discretion of the Compensation Committee. 

  

	 	•	 	Regional payout can occur if corporate results are profitableExecutive Agreement dated November 15, 2005

 Exhibit 10.28 
 AMENDMENT TO 
 EXECUTIVE TRANSITION AGREEMENT (“Amendment”) 
 WHEREAS, Thomas D. Kampfer (“Executive”) and Iomega Corporation previously entered into an Executive Transition Agreement (“Transition
Agreement”), with an effective date of July 26, 2005; and 
 WHEREAS, the parties have now mutually agreed to amend the Transition
Agreement. 
 NOW, THEREFORE, the parties agree as follows: 
 Amendment. The Transition Agreement is hereby amended as set forth below. 
 Transition. Section 1 of the
Transition Agreement is deleted and replaced as follows: 
 “The parties agree that Executive will remain employed by Iomega until
February 15, 2006 (“Transition Period”).” 
 Duties. Section 2 of the Transition Agreement is deleted and replaced as
follows: 
 “During the Transition Period, Executive will continue to report directly to Iomega’s chief executive officer
(“CEO”). Executive’s duties will consist of the following activities: 
  

	 	•	 	Begin the transition of duties from the current Chief Financial Officer (“CFO”) and ensure an orderly transition by November 11, 2005. 

  

	 	•	 	On November 11, 2005, assume the role of Interim CFO, including responsibility for the finance, accounting, tax, treasury, investor relations and legal functions.

  

	 	•	 	Complete the transition of REV OEM and business development activities to the Senior Director, REV Global Strategic Development by November 14, 2005. 

 

	 	•	 	Complete the transition of REV product generation activities to the Vice President, REV Product Generation and Planning by November 14, 2005. 

  

	 	•	 	Continue supporting Board of Directors-related and corporate governance matters and ensure an orderly transition of the General Counsel role during fourth quarter 2005.

 During the Transition Period, Executive will devote reasonable business efforts and time to Iomega and, so long as employed
by Iomega, shall remain subject to the Iomega Code of Conduct.” 
 Severance Benefits. Section 4 of the Transition Agreement is deleted and
replaced as follows: 
 “Upon expiration of the Transition Period, Executive shall receive severance benefits defined in Executive’s
letter agreement of employment dated July 23, 2001, a copy of which is attached as Exhibit A (the “Severance Benefits”); provided, however, that 1/12th of Executive’s annual base salary will be paid to him as a bonus on January 6, 2006 and 

  

 -1- 

 
another 1/12th of
Executive’s annual base salary will be paid to him on February 3, 2006 (collectively, the “Bonus”), and upon Executive’s departure from Iomega, his severance will be correspondingly reduced from 9 months to 7 months base
salary. Notwithstanding the Bonus, Executive will still receive reimbursement to continue all medical, health and life insurance benefits for nine months after his departure from Iomega.” 
 Death or Disability. Section 5 of the Transition Agreement is deleted and replaced as follows: 
 “Upon the disability (as defined in Section 22(e)(3) of the Internal Revenue Code of 1986, as amended) or death of Executive, employment shall
immediately terminate; however, Executive’s heirs would be eligible for and would receive the Bonus and Severance Benefits.” 
 Other.
Except as expressly stated herein, the Transition Agreement remains unchanged and in full force and effect. 
 Effective Date: October 21, 2005

  

									
	 Accepted and Agreed to:
	 		 	
			
	 Executive
	 		 	 Iomega Corporation

					
		 	/s/ Thomas D. Kampfer	 		 		 	/s/ Anna Aguirre
	  
	 		 	  

	 By:
	 		 		 	By:	 	
	 Name:
	 	 Thomas D. Kampfer
	 		 	 Name:
	 	Anna Aguirre
	 Title:
	 	 EVP and Secretary
	 		 	 Title:
	 	VP Human Resources
					
	 Date:
	 	 November 15, 2005
	 		 	 Date:
	 	November 14, 2005

  

 -2-Form of Stock Option Agreement for 2005 Stock and Incentive Plan.

 Exhibit 10.97 
 RITA MEDICAL SYSTEMS, INC. 
 2005 STOCK AND INCENTIVE PLAN 
 STOCK OPTION AGREEMENT 
 You
have been granted an option to purchase Common Stock of RITA Medical Systems, Inc. (the “Company”) as indicated on the Certificate of Stock Option Grant on the AST Stockplan website (the “Certificate”). Please
review the Certificate and this Stock Option Agreement before executing your grant at the AST Stockplan website at www.aststockplan.com. 
  

			
	Vesting/Exercise Schedule:	 	So long as your employment or consulting relationship with the Company continues, the Shares underlying this Option shall vest and become exercisable in accordance with the vesting schedule
indicated on the Certificate.
		
	Termination Period:	 	Option may be exercised for three months after termination of employment or consulting relationship except as set out in Section 5 of the Stock Option Agreement (but in no event later
than the Expiration Date). Optionee is responsible for keeping track of these exercise periods following termination for any reason of his or her service relationship with the Company. The Company will not provide further notice of such
periods.

 1. Grant of Option. The Company hereby grants you (“Optionee”), an
option (the “Option”) to purchase the total number of shares of Common Stock (the “Shares”) set forth in the Certificate, at the exercise price per Share set forth in the Certificate (the “Exercise
Price”) subject to the terms, definitions and provisions of the RITA Medical Systems, Inc. 2005 Stock and Incentive Plan (the “Plan”) adopted by the Company, which is incorporated in this Agreement by reference. Unless
otherwise defined in this Agreement, the terms used in this Agreement shall have the meanings defined in the Plan. This Stock Option Agreement shall be deemed executed by the Company and Optionee upon execution by such parties of the Certificate.

 2. Designation of Option. This Option is intended to be an Incentive Stock Option as defined in Section 422 of the Code
only to the extent so designated in the Certificate, and to the extent it is not so designated or to the extent the Option does not qualify as an Incentive Stock Option under Applicable Law, it is intended to be and will be treated as a Nonstatutory
Stock Option. 
 Notwithstanding the above, if designated as an Incentive Stock Option, in the event that the Shares subject to this Option
(and all other Incentive Stock Options granted to Optionee by 

 the Company or any Parent or Subsidiary, including under other plans of the Company) that first become exercisable in any
calendar year have an aggregate fair market value (determined for each Share as of the date of grant of the option covering such Share) in excess of $100,000, the Shares in excess of $100,000 shall be treated as subject to a Nonstatutory Stock
Option, in accordance with Section 5(c) of the Plan. 
 3. Exercise of Option. This Option shall be exercisable during its
term in accordance with the Vesting/Exercise Schedule set out in the Certificate and with the provisions of Section 10 of the Plan as follows: 
 (a) Right to Exercise. 
 (i) This Option may not be exercised for a fraction of a share. 
 (ii) In the event of Optionee’s death, disability or other termination of employment, the exercisability of the Option is governed by
Section 5 below, subject to the limitations contained in this Section 3. 
 (iii) In no event may this Option be exercised after
the Expiration Date of the Option as set forth in the Certificate. 
 (b) Method of Exercise. 
 (i) This Option shall be exercisable by delivering to the Company a Stock Option Cash Exercise Letter of Authorization which is a written notice of
exercise (in the form available from the AST Stockplan website) which shall state Optionee’s election to exercise the Option, the number of Shares in respect of which the Option is being exercised, and such other representations and agreements
as to the holder’s investment intent with respect to such Shares as may be required by the Company pursuant to the provisions of the Plan. The Cash Letter of Authorization shall be signed by Optionee and shall be delivered to the Company by
such means as are determined by the Administrator in its discretion to constitute adequate delivery. The Cash Letter of Authorization shall be accompanied by payment of the Exercise Price. This Option shall be deemed to be exercised upon receipt by
the Company of the Cash Letter of Authorization accompanied by the Exercise Price. 
 (ii) As a condition to the exercise of this Option and
as further set forth in Section 16 of the Plan, Optionee agrees to make adequate provision for federal, state or other tax withholding obligations, if any, which arise upon the vesting or exercise of the Option, or disposition of Shares,
whether by withholding, direct payment to the Company, or otherwise. 
 (iii) The Company is not obligated, and will have no liability for
failure, to issue or deliver any Shares upon exercise of the Option unless such issuance or delivery would comply with the Applicable Laws, with such compliance determined by the Company in consultation with its legal counsel. This Option may not be
exercised until such time as the Plan has been approved by the stockholders of the Company, or if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation of any applicable
federal or state securities or other law or regulation, 
  

 -2- 

 including any rule under Part 221 of Title 12 of the Code of Federal Regulations as promulgated by the Federal
Reserve Board. As a condition to the exercise of this Option, the Company may require Optionee to make any representation and warranty to the Company as may be required by the Applicable Laws. Assuming such compliance, for income tax purposes the
Shares shall be considered transferred to Optionee on the date on which the Option is exercised with respect to such Shares. 
 4.
Method of Payment. Payment of the Exercise Price shall be by any of the following, or a combination of the following, at the election of Optionee: 
 (a) cash or check; or 
 (b) delivery of a properly executed exercise notice together with irrevocable
instructions to a broker approved by the Company to deliver promptly to the Company the amount of sale or loan proceeds required to pay the exercise price. 
 5. Termination of Relationship. Following the date of termination of Optionee’s Continuous Service Status for any reason (the “Termination Date”), Optionee may exercise the Option
only as set forth in the Certificate and this Section 5. To the extent that Optionee is not entitled to exercise this Option as of the Termination Date, or if Optionee does not exercise this Option within the Termination Period set forth in the
Certificate or the termination periods set forth below, the Option shall terminate in its entirety. In no event, may any Option be exercised after the Expiration Date of the Option as set forth in the Certificate. 
 (a) Termination. In the event of termination of Optionee’s Continuous Service Status other than as a result of Optionee’s
disability or death, Optionee may, to the extent Optionee was vested in the Shares at the date of such termination (the “Termination Date”), exercise this Option during the Termination Period set forth in the Certificate.

 (b) Other Terminations. In connection with any termination other than a termination covered by Section 5(a), Optionee
may exercise the Option only as described below: 
 (i) Termination upon Disability of Optionee. In the event of termination of
Optionee’s Continuous Service Status as a result of Optionee’s disability, Optionee may, but only within six months from the Termination Date, exercise this Option to the extent Optionee was vested in the Shares as of such Termination
Date. 
 (ii) Death of Optionee. In the event of the death of Optionee (a) during the term of this Option and while an
Employee or Consultant of the Company and having been in Continuous Service Status since the date of grant of the Option, or (b) within thirty (30) days after Optionee’s Termination Date, the Option may be exercised at any time within
twelve months following the date of death by Optionee’s estate or by a person who acquired the right to exercise the Option by bequest or inheritance, but only to the extent the Shares are vested as of the Termination Date. 
 6. Non-Transferability of Option. Except as otherwise set forth in the Certificate, this Option may not be transferred in any manner
otherwise than by will or by the laws of descent 
  

 -3- 

 or distribution and may be exercised during the lifetime of Optionee only by him or her. The terms of this Option shall
be binding upon the executors, administrators, heirs, successors and assigns of Optionee. 
 7. Tax Consequences. Although
Optionee is being provided in the Plan prospectus a description of certain tax consequences of transactions related to the Option, Optionee remains responsible for all such tax consequences and the Company shall not be deemed to provide any
individual tax advice with respect thereto. Optionee should obtain advice from an appropriate independent professional adviser with respect to, and under the laws of Optionee’s state and country of residence and/or citizenship, the taxation
implications of the grant, exercise, assignment, release, cancellation or any other disposal of this Option and on any subsequent sale or disposition of the Shares. 
 8. Effect of Agreement. Optionee acknowledges receipt of a copy of the Plan and Plan prospectus and represents that he or she is familiar with the terms and provisions thereof (and has had an opportunity
to consult counsel regarding the Option terms), and hereby accepts this Option and agrees to be bound by its contractual terms as set forth herein and in the Plan. Optionee hereby agrees to accept as binding, conclusive and final all decisions and
interpretations of the Administrator regarding any questions relating to this Option. In the event of a conflict between the terms and provisions of the Plan and the terms and provisions of the Certificate and this Agreement, the Plan terms and
provisions shall prevail. This Option, including the Plan, constitutes the entire agreement between Optionee and the Company on the subject matter hereof and supersedes all proposals, written or oral, and all other communications between the parties
relating to such subject matter. 
 By your electronic signature and the electronic signature of the Company, you and the Company agree that
this Option is granted under and governed by the terms and conditions of the RITA Medical Systems, Inc. 2005 Stock and Incentive Plan which is attached and made a part of this document. 
 In addition, you agree and acknowledge that your rights to any Shares underlying the Option will be earned only as you provide services to the Company
over time, that the grant of the Option is not as consideration for services you rendered to the Company prior to your Vesting Commencement Date, and that nothing in the Certificate or the attached documents confers upon you any right to continue
your employment or consulting relationship with the Company for any period of time, nor does it interfere in any way with your right or the Company’s right to terminate that relationship at any time, for any reason, with or without cause.

 RITA Medical Systems, Inc. 
  

 -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]